investorscraft@gmail.com

Intrinsic ValueC4 Therapeutics, Inc. (CCCC)

Previous Close$2.66
Intrinsic Value
Upside potential
Previous Close
$2.66

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

C4 Therapeutics, Inc. operates in the biotechnology sector, specializing in targeted protein degradation therapies. The company leverages its proprietary TORPEDO platform to develop small-molecule degraders aimed at treating cancer and other diseases by selectively eliminating disease-causing proteins. This approach positions C4 Therapeutics at the forefront of precision medicine, competing with larger biopharmaceutical firms while focusing on novel mechanisms to address unmet medical needs. The company generates revenue primarily through collaborations, licensing agreements, and milestone payments from partners, reflecting a capital-efficient R&D model. Its pipeline includes preclinical and clinical-stage candidates targeting hematologic malignancies and solid tumors, with strategic partnerships enhancing its research capabilities. Despite being a clinical-stage biotech, C4 Therapeutics has carved a niche in the competitive oncology space by emphasizing differentiated science and collaborative innovation.

Revenue Profitability And Efficiency

C4 Therapeutics reported revenue of $35.6 million for the period, driven by collaboration agreements. The company posted a net loss of $105.3 million, reflecting significant R&D investments. Operating cash flow was negative $65.2 million, underscoring the capital-intensive nature of drug development. Capital expenditures were minimal at $180,000, indicating a lean operational model focused on advancing its pipeline rather than infrastructure.

Earnings Power And Capital Efficiency

The diluted EPS of -$1.52 highlights the company's current earnings challenges as it prioritizes pipeline growth. With $55.5 million in cash and equivalents, C4 Therapeutics maintains liquidity to fund near-term operations, though its $65.8 million total debt suggests reliance on external financing. The absence of dividends aligns with its reinvestment strategy in R&D to drive long-term value creation.

Balance Sheet And Financial Health

The balance sheet shows $55.5 million in cash against $65.8 million in total debt, indicating a leveraged position. With 69.4 million shares outstanding, the equity base supports ongoing funding needs. The company’s financial health hinges on successful clinical progress and securing additional partnerships or capital to sustain operations beyond the near term.

Growth Trends And Dividend Policy

Growth is tied to clinical milestones and partnership expansions, with no dividend policy in place. The focus remains on advancing its TORPEDO platform and pipeline candidates. Revenue growth will likely depend on collaboration milestones, while profitability may remain elusive until late-stage clinical success or commercialization.

Valuation And Market Expectations

The market likely values C4 Therapeutics based on its pipeline potential and platform technology rather than current earnings. Negative EPS and cash flow reflect the high-risk, high-reward nature of biotech investing. Investor sentiment will hinge on clinical data readouts and partnership announcements, which could drive valuation swings.

Strategic Advantages And Outlook

C4 Therapeutics’ strategic edge lies in its proprietary protein degradation technology and collaborative approach. The outlook depends on clinical success, with near-term catalysts including pipeline advancements and partnership milestones. Challenges include funding sustainability and competitive pressures, but the company’s innovative science positions it for long-term opportunities in targeted therapies.

Sources

10-K filing, company investor relations

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount